Africa Diabetes Drugs Market Analysis Report 2022 to 2030

Africa Diabetes Drugs Market Analysis

$ 3999

The Africa diabetes drugs market size was valued at $926.7 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1665 Mn in 2030. The market is segmented by drug type, application, and distribution channel. The African diabetes drug market will grow because the increasing prevalence of NCDs in Africa has contributed to the increasing prevalence of diabetes. The key market players are Johnson & Johnson, Novo Nordisk, Novartis, Merck, Eli Lilly and Company, and others.

ID: IN10AFPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Africa AUTHOR: Chandani Patel

Buy Now

Africa Diabetes Drugs Market Executive Summary

The Africa diabetes drugs market size was valued at $926.7 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1665 Mn in 2030. Healthcare expenditure in Africa is an important issue as it has a significant impact on the availability and quality of healthcare services in the continent. According to the World Health Organization, healthcare expenditure in Africa is generally low compared to other regions of the world. Currently, African countries spend $8 to $129 per capita on health. Increasing healthcare expenditure in Africa is critical to improving the availability and quality of healthcare services in the continent. This can be achieved through increased government funding for healthcare, as well as investment from the private sector and international aid organizations. By investing in healthcare, African countries can improve the health outcomes of their populations and contribute to economic development and poverty reduction.

Diabetes is a growing health concern in Africa, and both the prevalence and incidence rates of the disease have been increasing in recent years. According to the International Diabetes Federation (IDF), an estimated 19.4 Mn people had diabetes in Africa in 2019, and this number is expected to increase to 47.1 Mn by 2045. The IDF also reports that the prevalence of diabetes in adults in Africa is 3.8%, which is lower than the global average of 9.3%. However, this figure is believed to be an underestimate due to underdiagnosis and poor reporting in many African countries.

The incidence of diabetes in Africa is also increasing, with a rising number of cases being diagnosed each year. A study published in The Lancet in 2017 estimated that the incidence of diabetes in sub-Saharan Africa was increasing at a rate of 4.4% per year. This is much higher than the global average of 2.6% per year. Several factors contribute to the high rates of diabetes in Africa, including changing dietary habits, sedentary lifestyles, and a lack of access to healthcare services.

The development of novel medications to give diabetic patients more treatment options has been driven by the disease's increasing incidence, prevalence, and progressive nature. Currently, non-insulin medicines account for more than half of sales in the diabetes market and are the first-line medications for Type-2 diabetes patients. Two significant classes—sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors—have entered this market over the previous ten years (SGLT-2). For those with Type-2 diabetes, oral antidiabetic medications lower blood sugar levels in a variety of methods. Some of them increase pancreatic insulin secretion, while others enhance cell insulin sensitivity or stop the liver from producing glucose. Others reduce the rate of glucose absorption following meals.

Studies and advancements pertaining to medication compounds or formulation technologies have been ongoing. For instance, Hanmi Pharmaceutical reported in September 2021 that the results of its global, large-scale clinical trial with more than 4,000 patients added to the efficacy of the drug showed that efpeglenatide (GLP-1 RA), a new, long-acting diabetes biologic drug, significantly reduced incidences of major adverse cardiovascular events (MACE) and kidney disease. The Saudi government declared in July 2022 that the country has experienced an increase in the need for high-quality healthcare services as a result of changes, such as an aging population and a rise in the prevalence of lifestyle disorders like diabetes and obesity. Working on healthcare entities, certifications, and laws involves both the public and private sectors. The Saudi government is attempting to cost-effectively ensure accessibility, affordability, and high-quality primary care while also taking steps to ensure that all of its inhabitants are insured. The aforementioned factors will likely cause the market to expand throughout the course of the projected period.

africa diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Increasing prevalence of diabetes: 24 Mn adults (20-79) are living with diabetes in the IDF Africa Region in 2021. This figure is estimated to increase to 33 million by 2030 and 55 million by 2045.
52 Mn adults (20-79) in the IDF Africa Region have Impaired Glucose Tolerance (IGT) which places them at high risk of developing type 2 diabetes. his figures are estimated to reach 71 Mn by 2030 and 117 Mn by 2045. There the demand for diabetes treatment will increase in the coming years
Rising obesity rates: The WHO analysis finds that the prevalence of obesity among adults in the 10 high-burden countries will range from 13.6% to 31%, while in children and adolescents, it will range from 5% to 16.5%. Africa also faces a growing problem of overweight in children. In 2019, the continent was home to 24% of the world’s overweight children aged under 5. Being overweight has been associated with diabetes.
Technological advancements: Technology developments have resulted in the creation of novel, more potent diabetes medications. As these medications become more accessible, the market is anticipated to rise as a result.

Market Restraints

High cost of diabetes drugs: Many of the most recent diabetes treatments are highly expensive, which can restrict access for those who cannot afford them.
Limited access to healthcare: In many areas of Africa, particularly in rural and underserved communities, access to healthcare is limited. This can make it difficult for people to get the diabetes drugs they require.
Regulatory challenges: For pharmaceutical businesses, the regulatory climate in Africa can be difficult, which could impede the creation and marketing of novel diabetes medications.

Competitive Landscape

Key Players

Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Sanofi
Merck
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical Company Limited
Biocon ltd
Bristol-Myers Squibb
Boehringer Ingelheim
Novartis
GlaxoSmithKline
Lupin ltd
Piramal healthcare ltd
Ranbaxy laboratories ltd.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

African Medicines Agency (AMA): These disparities, capacity needs, and logistical challenges were among the reasons why the AU wanted to establish a continental regulatory system. And like other regulatory systems, the AMA is designed to protect people, to ensure that all Africans have access to safe, efficacious, and affordable products that meet international standards.

The AMA is based on the AU Model Law on Medical Products Regulation. In broad terms, its goal is harmonization by achieving the following:

Registration and marketing of health technologies
Granting manufacturing and distribution licenses
Conducting quality and safety inspection of health technologies and manufacturing facilities
Authorizing clinical trials through an established National Ethics Committee or Institutional Review Board
Overseeing appeals procedures through an established Administrative Appeals Committee

International reaction to the AMA has been mostly positive. The International Federation of Pharmaceutical Manufacturers & Associations, for example, said that the “AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.”

And just last month before a two-day EU-AU summit, the EU (including the European Commission, the European Medicines Agency, and member states Belgium, France, and Germany) and the Bill & Melinda Gates Foundation announced they would mobilize more than 100 million euros over the next five years to support the AMA and other pharma regulatory initiatives at regional and national levels.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.